Gastrointestinal Cancer Metastatic clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose escalation cohort has been completed. Expansion cohort is open for metastatic liver dominant neuroendocrine tumor.
Orange, California and other locations
Our lead scientists for Gastrointestinal Cancer Metastatic research studies include Nadine Abi-Jaoudeh, MD.